CLRB

Cellectar Biosciences Inc

CLRB, USA

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. It also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChem Bio. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.

https://www.cellectar.com

Stock Price

$0.00

0%

increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
CLRB
stock
CLRB

Meme Stocks: Will CLRB stock gain from lower inflation - Weekly Trading Summary & Fast Moving Stock Watchlists Bộ Nội Vụ

Read more →
CLRB
stock
CLRB

$CLRB stock is up 26% today. Here's what we see in our data. Quiver Quantitative

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$47

Analyst Picks

Strong Buy

1

Buy

1

Hold

2

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

1.13

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-47.38 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-30.38 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

High

0.56

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 5.73% of the total shares of Cellectar Biosciences Inc

1.

Vanguard Group Inc

(1.765%)

since

2025/06/30

2.

Vanguard Total Stock Mkt Idx Inv

(1.0962%)

since

2025/07/31

3.

Geode Capital Management, LLC

(0.4523%)

since

2025/06/30

4.

Vanguard Institutional Extnd Mkt Idx Tr

(0.4086%)

since

2025/07/31

5.

HRT FINANCIAL LLC

(0.394%)

since

2025/06/30

6.

Riverview Capital Advisers LLC

(0.3289%)

since

2025/06/30

7.

Fidelity Extended Market Index

(0.2366%)

since

2025/07/31

8.

BlackRock Inc

(0.1486%)

since

2025/06/30

9.

Dimensional US Small Cap ETF

(0.1442%)

since

2025/08/29

10.

UBS Group AG

(0.1134%)

since

2025/06/30

11.

Extended Equity Market Fund K

(0.0732%)

since

2025/06/30

12.

Fidelity Total Market Index

(0.0647%)

since

2025/07/31

13.

NT Ext Equity Mkt Idx Fd - NL

(0.0645%)

since

2025/06/30

14.

Spartan Extended Market Index Pool F

(0.0636%)

since

2025/07/31

15.

Northern Trust Extended Eq Market Idx

(0.0512%)

since

2025/06/30

16.

NT Ext Equity Mkt Idx Fd - L

(0.0512%)

since

2025/06/30

17.

Fidelity Series Total Market Index

(0.0512%)

since

2025/07/31

18.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0501%)

since

2025/06/30

19.

Vanguard Instl Ttl Stck Mkt Idx Tr

(0.0325%)

since

2024/12/31

20.

Spartan Total Market Index Pool G

(0.0299%)

since

2025/07/31

21.

Vanguard U.S. Eq Idx £ Acc

(0.0176%)

since

2025/07/31

22.

Morgan Stanley - Brokerage Accounts

(0.016%)

since

2025/06/30

23.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.0144%)

since

2025/06/30

24.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0122%)

since

2024/12/31

25.

Goldman Sachs Group Inc

(0.0113%)

since

2025/03/31

26.

State St US Extended Mkt Indx NL Cl C

(0.011%)

since

2025/08/31

27.

Extended Equity Market Fund M

(0.0092%)

since

2025/06/30

28.

SIMPLEX TRADING, LLC

(0.0075%)

since

2025/06/30

29.

Tower Research Capital LLC

(0.0061%)

since

2025/06/30

30.

SSgA U.S. Total Market Index Strategy

(0.0046%)

since

2025/03/31

31.

Group One Trading, LP

(0.0018%)

since

2025/06/30

32.

Advisor Group Holdings, Inc.

(0.0007%)

since

2025/06/30

33.

SBI Securities Co Ltd

(0.0003%)

since

2025/06/30

34.

U.S. Bancorp

(0.0001%)

since

2025/06/30

35.

JONES FINANCIAL COMPANIES LLLP

(0.0001%)

since

2025/06/30

36.

Bank of America Corp

(0.0001%)

since

2025/06/30

37.

HARBOUR INVESTMENTS, INC.

(0%)

since

2025/06/30

38.

Citigroup Inc

(0%)

since

2025/06/30

39.

State Street Corp

(0%)

since

2025/06/30

40.

Bfsg, LLC

(0%)

since

2025/03/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-1.41

EPS Estimate

-0.1386

EPS Difference

-1.2714

Surprise Percent

-917.316%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(5.5)
Defensive
Highly Defensive(6.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.3)
GARP
Not Attractive for GARP(1.5)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(3)
Net Net
Possible Net-Net(4)
Quality
Low Quality Business(2)
Value
Fair Value(4.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.